Published in JAMA on April 27, 2011
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) (TONIC) | NCT00063635
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2014) 2.90
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr (2012) 1.82
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol (2011) 1.52
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Relation between vitamin D status and nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr (2015) 1.44
Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr (2011) 1.35
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr (2013) 1.32
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A (2014) 1.24
Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol (2012) 1.19
A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr (2013) 1.15
Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol (2013) 1.15
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2013) 1.12
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 1.08
Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. J Pediatr (2013) 1.05
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol (2014) 1.02
Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol (2014) 1.01
Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol (2015) 1.00
Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr (2013) 1.00
Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol (2014) 0.99
Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care (2012) 0.99
Palmitate-induced activation of mitochondrial metabolism promotes oxidative stress and apoptosis in H4IIEC3 rat hepatocytes. Metabolism (2013) 0.98
Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol (2016) 0.97
Vitamin E inadequacy in humans: causes and consequences. Adv Nutr (2014) 0.97
Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr (2013) 0.97
Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care (2012) 0.96
Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.96
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol (2014) 0.96
Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr (2012) 0.95
Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable? Hepat Mon (2013) 0.94
Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol (2013) 0.93
Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol (2012) 0.93
Childhood obesity for pediatric gastroenterologists. J Pediatr Gastroenterol Nutr (2013) 0.93
Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One (2014) 0.92
Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2014) 0.92
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep (2012) 0.92
Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal (2013) 0.91
Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice. J Nutr (2012) 0.91
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs (2015) 0.91
Overweight and obesity in children and adolescents. J Clin Res Pediatr Endocrinol (2014) 0.91
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc (2015) 0.90
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.90
Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.89
OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci (2014) 0.89
Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients (2013) 0.89
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol (2014) 0.89
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr (2012) 0.89
Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. Diabetes (2013) 0.89
Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.89
Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol (2011) 0.89
Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats. Int J Mol Sci (2012) 0.88
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.88
A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci (2016) 0.87
Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol (2014) 0.87
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol (2012) 0.86
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Nutrients (2015) 0.85
Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. Adv Nutr (2014) 0.85
Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2014) 0.84
Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol (2015) 0.84
Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J (2013) 0.84
Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation. Pflugers Arch (2013) 0.84
Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol (N Y) (2014) 0.84
Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients (2016) 0.84
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther (2015) 0.84
Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat (2012) 0.83
Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol (2015) 0.83
Clinical trials: Trial design in NASH--realities and challenges. Nat Rev Gastroenterol Hepatol (2011) 0.83
Pediatric non-alcoholic fatty liver disease: New insights and future directions. World J Hepatol (2014) 0.83
A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice. PLoS One (2013) 0.83
Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Int J Prev Med (2013) 0.83
Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol (2012) 0.83
Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol (2015) 0.83
Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol (2015) 0.83
The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol (2016) 0.82
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia (2016) 0.82
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol (2014) 0.82
Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol (2015) 0.82
Role of vitamins in gastrointestinal diseases. World J Gastroenterol (2015) 0.82
Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol (2012) 0.82
Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children. Dig Dis Sci (2016) 0.82
High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery. Gastroenterology (2015) 0.81
Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood) (2015) 0.81
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol (2015) 0.81
Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations. Int J Obes (Lond) (2016) 0.81
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol (2012) 0.81
Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Ann Gastroenterol (2012) 0.81
Clinical advances in pediatric nonalcoholic fatty liver disease. Hepatology (2016) 0.81
Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.81
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol (2016) 0.81
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab (2016) 0.80
Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol (2014) 0.80
Role of the diet as a link between oxidative stress and liver diseases. World J Gastroenterol (2015) 0.80
Non-alcoholic Fatty liver disease in children. Curr Health Sci J (2014) 0.80
The α-tocopherol status and expression of α-tocopherol-related proteins in methionine-choline deficient rats treated with vitamin E. J Clin Biochem Nutr (2014) 0.80
The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr (2012) 0.80
Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. Case Rep Gastroenterol (2012) 0.80
The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med (2001) 37.70
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Metformin. N Engl J Med (1996) 7.66
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (2005) 4.21
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr (2000) 2.88
Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr (2003) 2.77
Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation (2008) 2.70
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology (2008) 2.33
Advances in pediatric nonalcoholic fatty liver disease. Hepatology (2009) 2.03
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2005) 1.86
Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol (2002) 1.72
Hepatocellular ballooning in NASH. J Hepatol (2010) 1.48
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials (2009) 1.48
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature (2008) 10.84
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med (2000) 8.32
Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med (2011) 7.81
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Brief communication: clinical implications of short-term variability in liver function test results. Ann Intern Med (2008) 5.27
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med (2013) 4.25
Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging (2008) 4.13
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med (2015) 3.79
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
AAV vector integration sites in mouse hepatocellular carcinoma. Science (2007) 3.73
The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis (2008) 3.69
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) (2011) 3.62
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med (2012) 3.51
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
Acute liver failure: Summary of a workshop. Hepatology (2008) 3.49
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol (2010) 3.36
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr (2006) 3.32
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr (2006) 3.03
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol (2007) 2.98
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol (2012) 2.89
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med (2010) 2.68
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med (2008) 2.61
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol (2013) 2.50
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48
Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr (2009) 2.46
Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol (2008) 2.45
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology (2010) 2.45